The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Auxilium Pharmaceuticals met expectations on revenue and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP loss per share dropped.
Margins improved across the board.
Auxilium Pharmaceuticals tallied revenue of $73.3 million. The 14 analysts polled by S&P Capital IQ expected revenue of $73.5 million on the same basis. GAAP reported sales were 19% higher than the prior-year quarter's $61.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.25. The 14 earnings estimates compiled by S&P Capital IQ averaged -$0.16 per share. GAAP EPS were -$0.25 for Q4 versus -$0.34 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 77.5%, 530 basis points better than the prior-year quarter. Operating margin was -16.4%, 1,000 basis points better than the prior-year quarter. Net margin was -16.2%, 1,030 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $72.0 million. On the bottom line, the average EPS estimate is -$0.13.
Next year's average estimate for revenue is $301.7 million. The average EPS estimate is -$0.45.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 125 members out of 178 rating the stock outperform, and 53 members rating it underperform. Among 56 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 29 give Auxilium Pharmaceuticals a green thumbs-up, and 27 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $21.73.
Over the decades, small-cap stocks like Auxilium Pharmaceuticals have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Auxilium Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.